OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(2)
Proteomics
(1)
Organisms
Alphavirus
(1)
Betaherpesvirinae
(1)
Brassica oleracea var. oleracea
(1)
Cowpox virus
(1)
Coxsackievirus
(1)
Cytomegalovirus
(1)
Dengue virus
(1)
EFO:0001352
(1)
Filoviridae
(1)
Hepatitis B virus
(1)
Human alphaherpesvirus 1
(1)
Human betaherpesvirus 5
(1)
Human immunodeficiency virus 1
(1)
Human immunodeficiency virus 2
(1)
Influenza A virus
(1)
Influenza C virus
(1)
Japanese encephalitis virus
(1)
Japanese encephalitis virus group
(1)
Lyssavirus rabies
(1)
Monkeypox virus
(1)
Nostoc sp. PCC 7120 = FACHB-418
(1)
Oropouche virus
(1)
Orthopoxvirus
(1)
Orthopoxvirus vaccinia
(1)
Rattus
(1)
Ruditapes decussatus
(1)
Tick-borne encephalitis virus
(1)
Viruses
(1)
West Nile virus
(1)
spotted fever group
(1)
Repository
pride
(1)
Tissue
Osteoblast
(1)
Disease
Bone osteosarcoma
(1)
Technology Type
Mass Spectrometry
(1)
Shotgun proteomics
(1)
Publication Date
2018
(1)
Release Date
2022
(1)
2012
(1)
Lab affiliation
Cornell University
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Euonymus alatus
Twig Extract Protects against Scopolamine-Induced Changes in Brain and Brain-Derived Cells via Cholinergic and BDNF Pathways.
Not available
S-EPMC9823662
|
biostudies-literature
Cite
ATR-mediated Proteome Remodeling is a Major Determinant of Homologous Recombination Capacity in Cancer Cells
DMSO or 5uM ATR inhibitor(VE-821) were treated for 8 days on U2OS cells prior to anlaysis.
ORGANISM(S):
Homo sapiens (Human)
2018-07-17
|
PXD010223
|
Pride
Atr inhibitor
Cite
A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study.
Not available
S-EPMC3446390
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
